title: Radial versus femoral access for rescue percutaneous coronary intervention with adjuvant glycoprotein IIb/IIIa inhibitor use.
abstract: BACKGROUND
  The transradial approach has not been evaluated for "rescue" percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa inhibitor following failed thrombolysis.
  
  
  OBJECTIVE
  To compare the safety and procedural outcomes of the transradial and transfemoral approaches to rescue PCI.
  
  
  METHODS
  Rescue PCI cases with adjuvant GP IIb/IIIa inhibitor performed at two centres were reviewed retrospectively, and the bleeding rates, equipment use and procedure times for the femoral and the radial approach were compared.
  
  
  RESULTS
  Radial access was attempted in 47 of 111 cases (42%) and crossover to femoral access was required in two cases (4%). Major bleeding occurred in three patients in the radial group (6%) and in 12 patients in the femoral group (19%; P=0.06). Radial access was associated with less access site-related major bleeding (0% versus 9%; P=0.04) and fewer transfusions (4% versus 19%; P=0.02). After excluding patients with intra-aortic balloon pump, this difference was no longer statistically significant (4% versus 8%; P=0.7). Fluoroscopy times and contrast use were similar, and the time to first balloon inflation was slightly longer with radial access (33 min versus 30 min; P=0.07).
  
  
  CONCLUSIONS
  In selected patients, the transradial approach for rescue PCI is safe and effective. The present findings warrant further study in a prospective, randomized trial.
authors.affiliation: St Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
authors.forename: Saleem
authors.initials: S
authors.lastname: Kassam
authors.forename: Warren J
authors.initials: WJ
authors.lastname: Cantor
authors.forename: Dharmesh
authors.initials: D
authors.lastname: Patel
authors.forename: Ian C
authors.initials: IC
authors.lastname: Gilchrist
authors.forename: Luke D
authors.initials: LD
authors.lastname: Winegard
authors.forename: Mark E
authors.initials: ME
authors.lastname: Rea
authors.forename: Kimberley A
authors.initials: KA
authors.lastname: Bowman
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Chisholm
authors.forename: Bradley H
authors.initials: BH
authors.lastname: Strauss
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D006328:Cardiac Catheterization / Q000379:methods*; D017023:Coronary Angiography; D004632:Emergency Medical Services / Q000379:methods; D005260:Female; D005263:Femoral Artery; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011336:Probability; D017534:Radial Artery; D012189:Retrospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex